Meet an Unreasonable Venture
CyanoCapture
Next generation oral GLP-1 drug delivery.
General Biotechnologies (2026) produces oral GLP-1s, insulin and peptides at a fraction of current costs.
Instead of using chemistry to manufacture drugs, edible microbes are genetically engineered to synthesise bespoke pharmaceutical molecules - turning ordinary cells into fully programmable biological factories. A 20g powder taken once daily with food, can deliver the oral dose of GLP-1s peptides for absorption via the gastrointestinal tract - eliminating the need for injections.
Notable Achievements
- Launching the US' first manufacturing of oral GLP-1 in Sacramento (Q3 2026).
- Secured $27m in LOIs and pre-orders to supply growth factors and insulin.
- Winner of the Elon Musk's Carbon Removal XPRIZE 2021.
Currently Operating in Four Regions
Press Mentions
February 18, 2026
CyanoCapture and Persist AI Announce Strategic Collaboration to Build World's First Robotic GMP Facility for Oral Protein and Peptide Drugs
CyanoCapture has partnered with Persist AI to develop the world's first robotic GMP facility for producing oral protein and peptide drugs. This collaboration highlights CyanoCapture's commitment to...
Read more »
October 30, 2025
Liverpool, CyanoCapture Team Up for Bionanotech Breakthrough
CyanoCapture collaborates with Liverpool researchers to advance bionanotechnology, focusing on enhancing carbon capture technologies through innovative cyanobacteria. This partnership aims to...
Read on Mirage News »More Ventures in Energy & Environment
Get the Unreasonable Newsletter
Get monthly updates on CyanoCapture and all of the other ventures working to solve global challenges.